Image Sourced Dorsavi Limited
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

ASM Technologies has signed a three-year contract with dorsaVi for 64 myViSafe kits.

ViSafe are wearable movement sensors which collect video and motion data, pinpointing unsafe work practices which may lead to serious injury.

This technology can be used to assess movement repetition, muscle activity and, challenging postures.

It can also be used in a range of workplaces from health care, hospitality, construction and, retail.

“The ViSafe study has proven to be a practical and essential tool to assess work activities, deciding on the purchase of developing plant and equipment for the future,” Sean Watters, Emergency Response Unit Manager said.

ASM Technologies will be using these kits to support self-managing handling risks and facilitating changes in manual handling.

These kits cost a total of $550k and delivery is expected to begin rolling out later in the year.

CEO of dorsaVi Dr. Andrew Ronchi is excited for his product to begin being used in workplaces.

“This is our largest rollout of myViSafe to a single organisation to date and I’m delighted to see myViSafe being incorporated into this large-scale workplace safety program,” he said.

Please find announcement attached here: https://hotcopper.com.au/data/pricesensitive/announcements/ASX/3A514309_DVL.html

DVL by the numbers
More From The Market Online

Recce Pharmaceuticals up 6% on new antibiotic production milestone

Recce Pharmaceuticals (ASX:RCE) is trading up more than 6 per cent after producing a 5000-dose batch…

Telix Pharmaceuticals granted US-FDA fast track designation for brain cancer detection

Telix Pharmaceuticals has been granted Fast Track designation by the FDA for its brain cancer imaging…

Atomo Diagnostics orders HIV self-test kits for third world countries

Atomo Diagnostics (ASX:AT1), has put in a purchase order from Viatris Healthcare for HIV self-tests, valued…

Imugene expands study for bile tract cancer patients

Imugene will be expanding its trial to treat gastrointestinal cancers - including bile tract cancer -…